Skip to content

H2020FP7HORIZON

Centre Hospitalier Universitaire Vaudois

Country
CHSwitzerland
Defence projects
0
Projects, all programmes
76
As coordinator
14
EU contribution (CORDIS)
EUR 24,817,125
Active
2008 to 2025

Projects

76 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
EHVAEuropean HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidatesH20202016ParticipantEUR 0
MEDICIS-PROMEDMEDICIS-produced radioisotope beams for medicineH20202015PartnerEUR 0
PROCROPProfessional cross-priming for ovary and prostate cancerH20202015ParticipantEUR 0
TBVAC2020TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical developmentH20202015ParticipantEUR 0
MOCHAModels of Child Health AppraisedH20202015ParticipantEUR 0
LIFEPATHLifecourse biological pathways underlying social differences in healthy ageingH20202015ParticipantEUR 0
COMBACTE-MAGNETCombatting Bacterial Resistance in Europe - Molecules against Gram Negative InfectionsFP72015ParticipantEUR 158,800
EbolaVacDevelopment of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire VaccineH20202014ParticipantEUR 0
COMBACTE-NETCombatting Bacterial Resistance in EuropeFP72013ParticipantNot stated
EUTEMPE-RXEUropean Training and Education for Medical Physics Experts in RadiologyFP72013ParticipantEUR 73,830
ANTIVESSEL-T-CELLSDevelopment of Vascular-Disrupting Lymphocyte Therapy for TumoursFP72013CoordinatorEUR 1,089,315
PROTECTCIdentify novel pathways to enhance the induction of protective CD8+ T cell responsesFP72013ParticipantEUR 541,436
EPIONENatural sensory feedback for phantom limb pain modulation and therapyFP72013ParticipantEUR 396,400
PHAGOBURNEvaluation of phage therapy for the treatment of Escherichia coli and Pseudomonas aeruginosa burn wound infections (Phase I-II clinical trial)FP72013ParticipantEUR 162,031
HBPThe Human Brain ProjectFP72013ParticipantEUR 1,795,969
LCMVACCProphylactic and therapeutic use of recombinant lymphocytic choriomeningitis virus against melanomaFP72012CoordinatorEUR 192,622
BRAINVECTORSFrom Brain Gene Transfer Towards Gene Therapy: Pharmacological Assessment of AAV, CAV and LVVFP72012CoordinatorEUR 446,279
HIT HIDDEN HIVPaving the way towards HIV eradication/controlFP72012ParticipantEUR 895,220
SYSCLADSystems prediction of Chronic Lung Allograft DysfunctionFP72012CoordinatorEUR 454,401
ADHOPHTAAdopting Hospital Based Health Technology Assessment in EUFP72012ParticipantEUR 187,119

The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.